Please login to the form below

Not currently logged in
Email:
Password:

Galbraith settles with Cohn & Wolfe

Rebecca Galbraith has settled court proceedings issued by global public relations agency Cohn & Wolfe, where she used to be board director

Rebecca Galbraith has settled court proceedings issued by the global public relations agency Cohn & Wolfe (C&W), where she was previously a board director.

Galbraith had been dismissed on grounds of gross misconduct a month after she handed in her notice at the agency.

In the proceedings at the high court, C&W alleged that Galbraith "acted in breach of contract and fiduciary duty by misappropriating proprietary information belonging to Cohn & Wolfe and preparing to actively compete with the agency while sitting as a board director."

As reported in PR Week, Galbraith said: "Firstly I wish to apologise unreservedly to Cohn & Wolfe and WPP for my actions, but secondly I wish to the apologise to the Cohn & Wolfe team in London."

She continued: "I accept my conduct was in breach of my legal obligations. I acknowledge I removed proprietary information belonging to Cohn & Wolfe but confirm that I did not open or disseminate that information to any third parties."

Galbraith has paid an undisclosed settlement. Her apology follows those of fellow former board directors, Fiona McMillan, who settled out of court on April 20 and, Jeremy Clark, who settled out of court on April 16.

4th May 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics